(+)-3-(ethoxy-d5)-17-methyl-(9α,3α,4α)-morphinan | 1216910-49-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (+)-3-(ethoxy-d5)-17-methyl-(9α,3α,4α)-morphinan
• 英文别名: (1S,9S,10S)-17-methyl-4-(1,1,2,2,2-pentadeuterioethoxy)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene
• CAS: 1216910-49-4
• 化学式: C₁₉H₂₇NO
• 分子量: 290.39
• InChiKey: DIWAJQNYTVAWMY-MXQXTHHDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  盐酸 、 (+)-3-(ethoxy-d5)-17-methyl-(9α,3α,4α)-morphinan 以 甲醇 为溶剂， 生成 (+)-3-(ethoxy-d5)-17-methyl-(9α,3α,4α)-morphinan hydrochloride
  参考文献：
  名称：

  [EN] MORPHINAN COMPOUNDS
  [FR] COMPOSÉS DU MORPHINANE

  摘要：

  本发明涉及新型的吗啡喃化合物及其可药用盐。本发明还提供了包含本发明化合物的组合物，以及在使用σ1受体激动剂且具有NMDA拮抗活性的药物治疗方法中使用该组合物来治疗疾病和状况。

  公开号：

  WO2010033801A1

文献信息

• MORPHINAN COMPOUNDS
  申请人：Graham Philip B.

  公开号：US20110257214A1

  公开（公告）日：2011-10-20

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.
• COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY
  申请人：Thomas Amanda

  公开号：US20120083487A1

  公开（公告）日：2012-04-05

  Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like.
• [EN] MORPHINAN COMPOUNDS<br/>[FR] COMPOSÉS DU MORPHINANE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2010033801A1

  公开（公告）日：2010-03-25

  This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has NMDA antagonist activity.

  本发明涉及新型的吗啡喃化合物及其可药用盐。本发明还提供了包含本发明化合物的组合物，以及在使用σ1受体激动剂且具有NMDA拮抗活性的药物治疗方法中使用该组合物来治疗疾病和状况。